

EXHIBIT B

Functional protein microarrays

David S Wilson and Steffen Nock*

Microarrays of immobilized functional proteins have the potential to increase dramatically the throughput of proteomic analysis. Micro-immunoassays, in which biological samples are exposed to arrays of immobilized antibodies, can be used for protein expression profiling. In addition, protein function can be elucidated by performing binding and enzymatic assays on arrays of biologically active proteins.

Addresses

Zyomyx, Inc., 26101 Research Road, Hayward, California 94545, USA
*e-mail: snock@zyomyx.com

Current Opinion in Chemical Biology 2001, 6:81–85

1367-5931/01/\$ – see front matter
© 2001 Elsevier Science Ltd. All rights reserved.

Published online 4 December 2001

Abbreviations

CD cluster of differentiation
ELISA enzyme-linked immunosorbent assay

Introduction

Biologists, chemists, materials scientists and engineers have collaborated to develop DNA microarrays, which make it possible, in theory, to monitor the expression levels of all genes in an organism simultaneously [1]. The key to this new technology has been the development of surface-based assays in which numerous probes are immobilized in a spatially addressable manner. Such assay formats lend themselves well to miniaturization and multiplexing. Similar approaches are now being employed for highly parallel, miniaturized protein analysis. In these cases, the immobilized material is protein or some substance capable of capturing proteins out of complex biological mixtures. The main benefits of these protein microarrays will be the amount of information that can be obtained as a function of research time and sample quantity. A single feature on a protein microarray may require the deposition of less than one picogram of protein, which is about one million times less than that typically used to coat one well of a 96-well microtiter plate. The theoretical benefits of protein microarrays and the history of their development are discussed in the review by Ekins in this issue. We limit ourselves here to applications in which proteins are arrayed onto surfaces in such a way that they maintain their native structures and activities. Other reviews in this issue cover arrays of peptides (see review by Frank) and tissues and cells (see review by Kallioniemi). For recent in depth reviews of protein microarrays, see [2,3*,4].

Although the invention of DNA arrays can provide inspiration and some technical leads for the development of protein biochips, the detailed methodology for building protein arrays will differ significantly from those made with DNA. The main reason for this is the tendency of proteins to

undergo denaturation and to exhibit non-specific binding to surfaces. For these reasons, it is important to array proteins, if possible, without allowing them to denature because of dehydration or to contact with commonly used device materials such as steel, plastics, glass, etc. Miniaturization makes these issues far more important because the surface to volume ratio increases dramatically as one decreases the sample volumes to nanoliter and picoliter scales. Despite these difficulties, important advances have appeared in the past year, enabling impressive applications of this burgeoning technology.


Engineering surfaces for protein immobilization

The types of surfaces to which proteins can be immobilized fall into two categories. The first and simplest type of immobilization is onto surfaces that have a high inherent binding energy to proteins in general. The most common of these substrates are hydrophobic plastics such as polystyrene, to which most proteins physically adsorb by van der Waals, hydrophobic and hydrogen-bonding interactions. This type of physical adsorption is generally used to immobilize 'capture antibodies' in enzyme-linked immunosorbent assays (ELISAs). The advantage of this type of immobilization is that it is very simple to perform, because it does not require any modification of the protein for its attachment to the surface. The disadvantage is that most of the immobilized protein can be inactivated because of denaturation and steric occlusion [5,6]. The physical adsorption of proteins onto surfaces also tends to be heterogeneous, with proteins clustering together in patches [7]. Similar heterogeneity is observed on other surfaces used for non-covalent protein adsorption, such as nitrocellulose and poly-lysine-coated glass.

Physical adsorption of proteins onto surfaces results from a large number of weak contacts, and can influence protein structure and activity. A preferred method relies on one or a small number of strong bonds between the protein and surface, leaving the protein largely unaltered, except in the vicinity of the contact point. Examples include covalent attachment of proteins [8*], immobilization of biotinylated proteins onto streptavidin-coated surfaces [9**,10], and immobilization of His-tagged proteins (proteins containing a poly-histidine sequence) onto Ni²⁺-chelating surfaces [11**]. One advantage of covalent and streptavidin-biotin-based attachment is that, following protein immobilization, the surface reactivity can be quenched by incubation with a small molecule. This can render the surface more protein-resistant than those with intrinsic protein-binding activity. Recent examples of covalent modification have utilized amine-reactive surfaces, which modify lysine sidechains [8*,12,13], and aldehyde-reactive surfaces, which react with oxidized glycoproteins [13].

Figure 1

Scheme for an idealized protein array. The underlying device material could be glass, silicon, or some other flat surface. A thin inorganic layer such as a noble metal or metal oxide is applied to this surface and can facilitate detection of protein-binding events (e.g. a gold layer for surface plasmon resonance). On top of this inorganic layer is assembled an organic thinfilm in which the omega functionality is hydrophilic [14]. This monolayer coats the chip surface, making it protein-resistant. The chip is patterned [41,42] in such a way, however, that it contains features that are coated by mixed monolayers in which a fraction of the omega functionalities possess a group (X) that can react with a moiety (Y) engineered into a specific site on the proteins to be immobilized. The engineered protein is therefore oriented on the surface such that the active site or binding site faces away from the thinfilm and can therefore interact optimally with proteins in the biological sample. The figure shows two features, each derivatized with a different



Current Opinion In Chemical Biology

capture agent, and separated by a completely protein-resistant patch. After immobilizing different proteins onto different patches,

a complex protein mixture can be applied to the chip and each feature will capture specific proteins while repelling others.

Surfaces can be engineered to avoid non-specific protein adsorption [14], while making specific interactions with proteins of interest. An optimal composition of a protein microarray based on these principles is outlined in Figure 1. One method for accomplishing this is to derivatize surfaces with poly(ethylene glycol), which is known to repel non-specific protein adsorption [14,15]. By derivatizing a fraction of the poly(ethylene glycol) chains with biotin, streptavidin can be specifically attached to the surface. Because streptavidin is tetrameric, biotinylated proteins can in turn be immobilized. This method of attaching specific proteins to otherwise protein-resistant surfaces has been used to generate high-density protein microarrays of very high quality [9**,10].

To increase the number of proteins that can be immobilized per unit area, Mirzabekov and colleagues attach gel pads to surfaces, thus giving the features a third dimension, preventing rapid evaporation and creating barriers between features. This approach is described by Mirzabekov in this issue.

Engineering proteins for surface attachment

The most common method for immobilizing proteins through covalent (or biotin-based) interactions is by randomly conjugating lysine residues on proteins to amine-reactive surfaces (or biotinylation reagents). When the structure of a protein is known, it may be advantageous to immobilize it in such a way that the protein is attached to the surface in a unique orientation in which the biologically important site faces away from the surface. This is most easily achieved when using recombinant proteins, in which amino- or carboxy-terminal tags can be introduced. A His-tag can be used to immobilize proteins in an oriented

fashion [11**], as can an amino-terminal serine or threonine residue [16]. For non-recombinant proteins, one must take advantage of existing functional groups on the protein. Several methods have been developed to orient antibodies and their fragments on surfaces (reviewed in [17]). Antibodies contain a conserved glycosylation site on the Fc domain (the crystallizable domain of immunoglobulin G), and this can be oxidized and then biotinylated using biotin hydrazide. Alternatively, antibodies can be cleaved by pepsin into dimeric Fab' fragments (antigen-binding fragments of immunoglobulin G) [18], which are linked together by disulfide bonds in the hinge region. The disulfides can be reduced and then conjugated to a thiol-reactive surface or biotin-maleimide. Using either of these methods, the antibodies or Fab' fragments are oriented in such a way that the antigen-binding sites face away from the surface. Several studies have shown that these oriented antibodies retain a higher and more homogeneous level of activity than randomly oriented ones (see [19*] and references therein). Full-length antibodies can also be oriented onto surfaces through binding to immobilized protein A or G [19*], but this interaction may not be stable enough for some applications.

Methods for printing proteins

Robotic printing of proteins onto surfaces has been performed using instruments designed for DNA spotting [11**,20,21,22**,23,24]. One drawback to this approach is the long printing times that, coupled with the small volumes that are spotted onto the surfaces, generally result in drying of the protein spots. To ameliorate this problem, MacBeath and Schreiber [8*] humidified the spotting chamber and also added glycerol to the protein solutions. Other printing methods include deposition by a hydrogel

Table 1**Applications of functional protein microarrays.**

Application	No. proteins	Detection	Refs
Antibody arrays			
Protein profiling (proof of concept)	115	Fluorescent analyte	[20]
Measurement of protein abundances in blood	3	Sandwich ELISA/ fluorescence	[24]
Measurement of cytokine abundances	7, 24	Sandwich ELISA/ chemiluminescence	[22*,35]
Capture of leukocytes/ phenotyping leukemias	60	Light microscopy	[36*]
Antigen arrays			
Reverse immunoassay to measure autoimmune antibodies	18	ELISA/ chemiluminescence	[25]
Reverse immunoassays to measure allergies	5*	Rolling circle DNA synthesis fluorescent probe	[38]
Immobilized proteins from cDNA libraries			
Kinase substrate specificity	119	Radioassay	[12]
Identification of calmodulin- and phospholipid-binding proteins	5800	Fluorescent probe	[11*]

*In this case, each feature was a complex protein mixture from common allergens.

stamper inked with an aqueous protein solution [25], inkjet printing [26,27], electrospray through a dielectric grid mask [28,29], and direct application of protein solutions via microfluidic networks [30,31*]. With all of these methods, the challenge is to keep the proteins hydrated at all times and to minimize the denaturing of proteins by various device materials and by the liquid-air interphase. This is an area with considerable need for innovation and improvement.

Applications of protein arrays

Recent applications of protein biochips are listed in Table 1. The most common use of these microarrays is the micro-immunoassay, in which arrays of different capture antibodies are immobilized and subsequently exposed to a biological sample. Analyte proteins bind to the immobilized capture agents and are then detected by fluorescence, luminescence, etc. Various protein-binding agents generated from combinatorial methods may also be used in place of traditional antibodies, such as artificial proteins [32], RNA or DNA aptamers [33], allosteric ribozymes [34], peptides, small molecules, and so on [3*]. The largest number of capture agents to be immobilized on an array was described by Haab *et al.* [20]. They spotted 115 different antibodies onto a slide array, and incubated it with a mixture of fluorescently labeled protein antigens. Sixty percent of the antibodies tested could give a qualitative indication of the presence of their cognate proteins at the highest concentration of antigens tested ($1.6 \mu\text{g ml}^{-1}$), but only about 23% of the antibodies gave quantitative data at this concentration. The fraction of the antibodies that provided useful signal declined with decreasing antigen concentration, and the presence of large amounts of non-antigen (serum) proteins also decreased the sensitivity of the measurement by increasing the background fluorescence.

An alternative to the detection of labeled analytes is a 'sandwich assay', which utilizes two antibodies that simultaneously bind the same antigen: one antibody is immobilized onto the surface, and the other one is fluorescently labeled or conjugated to an enzyme that can produce a fluorescent, luminescent or colored product when supplied with the appropriate substrate. The disadvantage of this

approach is that it requires two specific binding agents for each protein that is to be measured; the advantage is that sample labeling, which can be rather variable between samples [20], is not required; also specificity is higher in sandwich assays because two different reagents must simultaneously recognize the protein to produce signal. Using a sandwich approach, Huang *et al.* [35] have described a simple, low-density filter-based array to measure 25 cytokines in parallel, and achieved detection levels compatible with physiological protein concentrations. Higher-density arrays of antibodies against cytokines and other medically important proteins have also been developed [22**,23,24]. In these cases, the arrays were printed into wells of 96-well microtiter plates, giving microarrays within macroarrays.

Antibody arrays have also been used to capture entire cells. Belov *et al.* [36**] constructed arrays of 60 different antibodies against CD (cluster of differentiation) antigens. Leukocytes from the blood of leukemia patients were exposed to the array, washed, and the pattern of cells binding to the different features was analyzed by light microscopy. Leukocytes express on their plasma membranes different subsets of CD antigens depending on the type of leukemia, so the binding pattern of cells on the array can be used for diagnosis, as well as drug target discovery.

Reverse immunoassays have also been used in microarray formats. In these cases, purified antigens or extracts from tissues or allergenic substances are immobilized on the surface and subsequently probed with antibodies to known proteins [37] or with serum. In the latter case, patients can be diagnosed for various autoimmune diseases [21] or allergies [38,39].

Not only protein abundance, but also activity can be evaluated in microarray formats, provided that the native protein fold is preserved after immobilization [40]. Zhu *et al.* [12] cloned and arrayed into 'nanowells' 119 of the 122 known protein kinases in yeast, and then assayed their specificity by exposing the array to 17 different substrates in the presence of radio-labeled ATP. By following the incorporation of radio-labeled phosphate into the array, they defined the substrate specificity of nearly all the

protein kinases from this organism. In an even larger scale effort [11**], the same group accomplished the monumental task of cloning, expressing, purifying and arraying 80% of the yeast proteome. Each of the 5800 open reading frames was cloned into a yeast expression vector that encodes a fusion protein with glutathione-S-transferase and a His-tag. Expression and purification was performed in microtiter plates, and 10–950 femtograms of each protein were arrayed at a density of about 100 features per square mm. A Ni²⁺-chelating surface was used, thus allowing for oriented attachment of the recombinant proteins. This approach identified 6 of the 12 known calmodulin-binding proteins (the others were either not in the library or were not expressed at detectable levels). A number of lipid-binding proteins were also found. It is clear that the proteome arrays from yeast and other organisms will be exploited for numerous creative applications in the future.

Conclusions and future prospects

Many important developments in the generation and utilization of functional protein microarrays have been reported in the past year. Groups from widely diverse fields, with different expertise, have reported advances in microdevice design, surface chemistry, bioconjugation chemistry and microassay development. Simultaneously, several creative biological applications of this new technology have emerged. Some applications are sufficiently robust that they can be carried out using simple protocols and off-the-shelf reagents, whereas others will require sophisticated chemistry and device design. The more quantitative and delicate systems will benefit from closer collaborations between scientists in these different disciplines, so that the best devices, surfaces, and experimental protocols will be applied to the most important biological and medical problems. To date, multiplexed microimmunoassays have constituted the most common uses of protein microarrays. Because immunoassays rely the immobilization of fully functional proteins, lessons gained from optimizing these systems will be instructive for the design of more complex micro-analytical devices for the parallel characterization of the enzymatic and binding activities of proteins.

Update

Recent work [43] demonstrates that protein microarray analysis can be combined with laser capture microdissection (LCM), to analyze cell population's tissues containing either normal, pre-malignant, or invasive carcinoma cells. Proteins from the LCM-purified cell types were extracted under denaturing conditions, randomly biotinylated and then incubated on a microarray of 368 different antibodies, most of which were raised against proteins involved in cancer, cell growth or signaling. The arrays were then washed and protein binding was detected based on the biotin tags on the extracted proteins. Using this approach, several proteins were identified as being differentially regulated upon tumor progression. Differences were also found in the stromal tissue surrounding the carcinoma cells. Most of

the identified proteins are known to be involved in signal-transduction pathways.

Acknowledgements

We thank Peter Wagner and the scientific staff at ZymoGenex for many important discussions.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
 - of outstanding interest
1. DeRisi JL, Iyer VR, Brown PO: Exploring the metabolic and genetic control of gene expression on a genomic scale. *Science* 1997, 278:680-686.
 2. Jenkins RE, Pennington SR: Arrays for protein expression profiling: towards a viable alternative to two-dimensional gel electrophoresis? *Electrophoresis* 2001, 21:13-29.
 3. Kodadek T: Protein microarrays: prospects and problems. *Chem Biol* 2001, 8:105-15.
 4. Cahill DJ: Protein and antibody arrays and their medical applications. *J Immunol Methods* 2001, 250:81-91.
 5. Butler JE, Ni L, Nessler R, Joshi KS, Suter M, Rosenberg B, Chang J, Brown WR, Cantarero LA: The physical and functional behavior of capture antibodies adsorbed on polystyrene. *J Immunol Methods* 1992, 150:77-90.
 6. Butler JE, Ni L, Brown WR, Joshi KS, Chang J, Rosenberg B, Voss EW: The immunochemistry of sandwich ELISAs. VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluoresceyl capture antibodies (Cabs) are denatured by passive adsorption. *Mol Immunol* 1993, 30:1165-1175.
 7. Nygren H: Experimental demonstration of lateral cohesion in a layer of adsorbed protein and in layers of gold-antibody complexes bound to surface immobilised antigen. *J Immunol Methods* 1988, 114:107-114.
 8. MacBeath G, Schreiber SL: Printing proteins as microarrays for high-throughput function determination. *Science* 2000, 289:1760-1763.
 9. Ruiz-Taylor LA, Martin TL, Zaugg FG, Witte K, Indermuhle P, Nock S, •• Wagner P: Monolayers of derivatized poly(L-lysine)-grafted poly(ethylene glycol) on metal oxides as a class of biomolecular interfaces. *Proc Natl Acad Sci USA* 2001, 98:852-857.
 10. Ruiz-Taylor LA, Martin TL, Wagner P: X-ray photoelectron spectroscopy and radiometry studies of biotin-derivatized poly(L-lysine)-grafted-poly(ethylene glycol) monolayers on metal oxides. *Langmuir* 2001, in press.
 11. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, Lan N, •• Jansen R, Bidlingmaier S, Houfek T et al: Global analysis of protein activities using proteome chips. *Science* 2001, 293:2101-2105.
 12. Zhu H, Klemic JF, Chang S, Bertone P, Casamayor A, Klemic KG, Smith D, Gerstein M, Reed MA, Snyder M: Analysis of yeast protein kinases using protein chips. *Nat Genet* 2000, 26:283-289.
 13. Arenkov P, Kukhtin A, Gemmell A, Voloshchuk S, Chupeeva V, Mirzabekov A: Protein microchips: use for immunoassay and enzymatic reactions. *Anal Biochem* 2000, 278:123-131.
 14. Prime KL, Whitesides GM: Self-assembled organic monolayers: model systems for studying adsorption of proteins at surfaces. *Science* 1991, 252:1164-1167.
 15. Kenausis GL, Voros J, Elbert DL, Huang N, Hofer R, Ruiz-Taylor L, Textor M, Hubbell JA, Spencer ND: Poly(L-lysine)-g-poly(ethylene

- glycol) layers on metal oxide surfaces: attachment mechanism and effects of polymer architecture on resistance to protein adsorption. *J Phys Chem B* 2000, 104:3298-3309.
16. Gaertner HF, Olford RE: Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. *Bioconjug Chem* 1996, 7:38-44.
 17. Lu B, Smyth MJ, O'Kennedy R: Oriented immobilization of antibodies and its applications to immunoassays and immunosensors. *Analyst* 1996, 121:29R-32R.
 18. Wilson DS, Wu J, Peluso P, Nock S: Improved method for pepsinolysis of mouse IgG₁ molecules to F(ab')₂ fragments. *J Immunol Methods* 2001, in press.
 19. Vijayendran RA, Leckband DE: A quantitative assessment of heterogeneity for surface-immobilized proteins. *Anal Chem* 2001, 73:471-480.
Demonstration that specifically orienting capture antibodies results in more homogeneous binding to analytes. Excellent bibliography of previous work showing higher activity of specifically versus randomly oriented proteins on surfaces.
 20. Haab BB, Dunham MJ, Brown PO: Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. *Genome Biol* 2001, 2:on-line citation RESEARCH0004.1-0004.13.
 21. Joos TO, Schrenk M, Hopfi P, Kroger K, Chowdhury U, Stoll D, Schorner D, Dur M, Herick K, Rupp S et al.: A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. *Electrophoresis* 2000, 21:2641-2650.
 22. Moody MD, Van Ardel SW, Orencole SF, Burns C: Array-based ELISAs for high-throughput analysis of human cytokines. *BioTechniques* 2001, 31:186-194.
A microarray of anti-cytokine antibodies within a macroarray (96-well plate, see also references [23,24]), enabling the simultaneous detection of seven cytokines.
 23. Mendoza LG, McQuary P, Mongan A, Gangadharan R, Brignac S, Eggers M: High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA). *BioTechniques* 1999, 27:778-6, 788.
 24. Wiese R, Belosludtsev Y, Powdrill T, Thompson P, Hogan M: Simultaneous multianalyte ELISA performed on a microarray platform. *Clin Chem* 2001, 47:1451-1457.
 25. Martin BD, Gaber BP, Patterson CH, Turner DC: Direct protein microarray fabrication using a hydrogel 'stamper'. *Langmuir* 1998, 14:3971-3975.
 26. Roda A, Guardigli M, Russo C, Pasini P, Baraldini M: Protein microdeposition using a conventional ink-jet printer. *BioTechniques* 2000, 28:492-496.
 27. Silzel JW, Cercek B, Dodson C, Tsay T, Obremski RJ: Mass-sensing, multianalyte microarray immunoassay with imaging detection. *Clin Chem* 1998, 44:2036-2043.
 28. Morozov VN, Morozova TY: Electrospray deposition as a method to fabricate functionally active protein films. *Anal Chem* 1999, 71:1415-1420.
 29. Moerman R, Frank J, Marijnissen JC, Schalkhammer TG, van Dedem GW: Miniaturized electrospraying as a technique for the production of microarrays of reproducible micrometer-sized protein spots. *Anal Chem* 2001, 73:2183-2189.
 30. Rowe CA, Scruggs SB, Feldstein MJ, Golden JP, Ligler FS: An array immunosensor for simultaneous detection of clinical analytes. *Anal Chem* 1999, 71:433-439.
 31. Bernard A, Michel B, Delamarche E: Micromosaic immunoassays. • *Anal Chem* 2001, 73:8-12.
A novel method for making arrays, also described in [30], in which proteins are applied to a surface using microfluidic channels, resulting in stripes of immobilized capture agents. Orthogonal parallel channels are then created to deliver samples that intersect with the original stripes, producing fluorescent signal when the immobilized protein binds to the sample.
 32. Nygren PA, Uhlen M: Scaffolds for engineering novel binding sites in proteins. *Curr Opin Struct Biol* 1997, 7:463-469.
 33. Brody EN, Willis MC, Smith JD, Jayasena S, Zichi D, Gold L: The use of aptamers in large arrays for molecular diagnostics. *Mol Diagn* 1999, 4:381-388.
 34. Seetharaman S, Zivarts M, Sudarsan N, Breaker RR: Immobilized RNA switches for the analysis of complex chemical and biological mixtures. *Nat Biotechnol* 2001, 19:336-341.
 35. Huang RP, Huang R, Fan Y, Lin Y: Simultaneous detection of multiple cytokines from conditioned media and patient's sera by an antibody-based protein array system. *Anal Biochem* 2001, 294:55-62.
 36. Belov L, de la Vega O, dos Remedios CG, Mulligan SP,
• Christoperson RL: Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. *Cancer Res* 2001, 61:4483-4489.
Anti-CD antibodies are used to capture cells. The cell-binding pattern gives a molecular phenotype characteristic of different types of leukemia.
 37. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin EF III, Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. *Oncogene* 2001, 20:1981-1989.
 38. Wiltshire S, O'Malley S, Lambert J, Kukanski K, Edgar D, Kingsmore SF, Schweltzer B: Detection of multiple allergen-specific IgEs on microarrays by immunoassay with rolling circle amplification. *Clin Chem* 2000, 46:1990-1993.
 39. Schweltzer B, Wiltshire S, Lambert J, O'Malley S, Kukanski K, Zhu Z, Kingsmore SF, Lizardi PM, Ward DC: Immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection. *Proc Natl Acad Sci USA* 2000, 97:10113-10119.
 40. Zhu H, Snyder M: Protein arrays and microarrays. *Curr Opin Chem Biol* 2001, 5:40-45.
 41. Blawas AS, Reichert WM: Protein patterning. *Biomaterials* 1998, 19:595-609.
 42. Kane RS, Takayama S, Ostuni E, Ingber DE, Whitesides GM: Patterning proteins and cells using soft lithography. *Biomaterials* 1999, 20:2363-2376.
 43. Knezevic K, Leethanakul C, Bichsel VE, Worth JM, Prabhu VV, Gutkind JS, Liotta LA, Munson PJ, Petricoin EF III, Krizman DB: Proteomic profiling of the cancer microenvironment by antibody arrays. *Proteomics* 2001, 1:1271-1278.